Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases-Reference-Cited by-同舟云学术

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Published:2018-01-23 Issue:3 Volume:61 Page:1130-1152
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vazquez Michael L.¹^ORCID,Kaila Neelu¹,Strohbach Joseph W.¹,Trzupek John D.¹,Brown Matthew F.²,Flanagan Mark E.²,Mitton-Fry Mark J.²,Johnson Timothy A.³,TenBrink Ruth E.⁴,Arnold Eric P.²,Basak Arindrajit²,Heasley Steven E.²,Kwon Soojin²,Langille Jonathan²,Parikh Mihir D.²,Griffin Sarah H.⁵,Casavant Jeffrey M.²,Duclos Brian A.³,Fenwick Ashley E.³,Harris Thomas M.²,Han Seungil²,Caspers Nicole²,Dowty Martin E.⁶,Yang Xin²,Banker Mary Ellen²,Hegen Martin⁷,Symanowicz Peter T.⁷,Li Li⁷,Wang Lu⁷,Lin Tsung H.⁷,Jussif Jason⁷,Clark James D.⁷,Telliez Jean-Baptiste⁷,Robinson Ralph P.²^ORCID,Unwalla Ray¹^ORCID

Affiliation:

1. Medicine Design, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States

2. Medicine Design, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States

3. Veterinary Medicine Research and Development, Pfizer Inc, 333 Portage Street, Kalamazoo, Michigan 49007, United States

4. Medicinal Chemistry, Pfizer Inc, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, United States

5. Chemical Research Development, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340, United States

6. Medicine Design, Pfizer Inc, 1 Burtt Road, Andover, Massachusetts 01810, United States

7. Inflammation and Immunology, Pfizer Inc, 1 Portland Street, Cambridge, Massachusetts 02139, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01598

Reference48 articles.

1. JAKS AND STATS: Biological Implications

2. Janus kinases in immune cell signaling

3. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency

4. JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

5. Regulation of JAK–STAT signalling in the immune system

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visible light–driven organic synthesis under other miscellaneous photocatalysis;Visible Light-Driven Organic Synthesis;2025

2. A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect;European Journal of Medicinal Chemistry;2024-11

3. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

4. Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis;Life;2024-09-06

5. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities;Bioorganic & Medicinal Chemistry Letters;2024-09